Monique Schiersing
Investment Director @ Roche Venture Fund
Monique Schiersing is a Series A investor at Roche Venture Fund focused on Biotechnology and Medical. Monique Schiersing - Investment Director @ Roche Venture Fund
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Monique Schiersing invests in
Stages Monique Schiersing invests in
Countries Monique Schiersing invests in
Investment Focus
Industry
- Biotechnology 4 (67%)
- Medical 2 (33%)
- Life Science 2 (33%)
- Pharmaceutical 2 (33%)
- Genetics 1 (17%)
Stage
- Series A 3 (50%)
- Series B 2 (33%)
Country
- United States 2 (33%)
- Spain 1 (17%)
- Switzerland 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M / Series B / May 27, 2025 | |
|
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | Series A / Jan 05, 2024 | |
Bonum Therapeutics
|
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management. | $93M / Series A / Nov 15, 2022 | |
Good Therapeutics
|
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer,more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology. | $8M / Series B / Dec 30, 2021 | |
|
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $49.3M / Series A / Nov 05, 2021 | |
Minoryx Therapeutics
|
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $21.3M / Series A / Oct 14, 2015 |
Co-Investors
About Roche Venture Fund
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Roche Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carole Nuechterlein
Head of Roche Venture Fund
|
|||
|
Monique Schiersing
Investment Director
|
|||
Simon Greenwood
Investment Director
|
|||
Simon Meier
Investment Director
|
|||
Nisha Marathe
Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Monique Schiersing invest in?
Monique Schiersing invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Monique Schiersing last invest?
The most recent investment recorded for Monique Schiersing closed in May 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
